PharmEnable Therapeutics is breaking down the barriers of inaccessibility: for the patient, the target and the drug.
A pioneering drug discovery company, PharmEnable leverages artificial intelligence to reimagine small molecules.
Working on targets that require the exquisite specificity of biologics, it is creating much-needed treatments particularly for cancer and neurological conditions.
The team is developing a pipeline of life-changing small molecule drugs with antibody-like selectivity targeting hard-to-reach areas.
It is also working with partners across disease areas, where achieving drug selectivity and optimal properties poses a significant challenge.
“Our aim is to replicate the specificity of biologics in the powerful and scalable form of a small molecule, to treat devastating diseases where there are currently no treatment options.”
Innovating small molecule drugs discovery with AI technology at PharmEnable
PharmEnable’s mission is to develop innovative drugs that target challenging disease areas, particularly in oncology and neurology. Their focus is on discovering small-molecule medicines through advanced AI technology. By leveraging their proprietary AI-enabled platform, chemSEEK, PharmEnable aims to unlock novel chemical spaces and create therapeutics with high specificity and efficacy. Their goal is to address unmet medical needs and improve patient outcomes by providing new treatment options for diseases that currently lack effective therapies.
PharmEnable has made significant strides in drug discovery. One of their notable achievements is the development of small molecule drugs that mimic the specificity of biologics, targeting hard-to-reach areas within the body. This includes their work on creating life-changing medicines for cancer and neurological diseases. Their innovative platform has enabled them to explore previously inaccessible targets, leading to the discovery of novel drug candidates with improved selectivity and reduced side effects.
The PharmEnable team
In 2023, PharmEnable secured substantial funding to support their research and development efforts. They closed a $7.5 million Pre-Series A financing round led by MP Healthcare, the venture arm of Mitsubishi Tanabe Pharma Group. This funding round also saw participation from existing investors such as Cambridge Enterprise Ventures, Parkwalk Advisors, and numerous other life sciences investors. These funds will be used to advance PharmEnable’s portfolio of projects in oncology and neurology, as well as to support further platform development.
